title: Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity.
abstract: OBJECTIVE
  The extent and predictors of liver fibrosis were examined in a HIV/HBVcoinfected cohort with extensive exposure to anti-HBV active HAART.
  
  
  METHODS
  Liver fibrosis was measured using transient elastography.
  
  
  RESULTS
  Thirty-seven patients of a median age of 43 were included in the study. All but 2 patients had received anti-HBV drugs for a median time of 40 months in the context of HAART. F0-F1 METAVIR fibrosis scores (minimal or no fibrosis) as measured by elastography were found in 21 (57%) patients. AST levels were significantly lower among F0-F1 patients (33 IU/L) compared to F2-F4 patients (48 IU/L) (p = .01). ALT levels were also lower in F0-F1 patients (38 IU/L) than in F2-F4 patients (54 IU/L) (p = .05).
  
  
  CONCLUSIONS
  In this HIV/HBV-coinfected cohort, with extensive HAART exposure including anti-HBV agents, more than half of the patients had no or minimal liver fibrosis. Higher transaminase levels were recognized in patients with higher degree of fibrosis.
authors.affiliation: Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
authors.forename: Ivana
authors.initials: I
authors.lastname: Maida
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
authors.forename: Carol
authors.initials: C
authors.lastname: Castellares
authors.forename: Belén
authors.initials: B
authors.lastname: Ramos
authors.forename: Giovanni
authors.initials: G
authors.lastname: Sotgiu
authors.forename: Luz
authors.initials: L
authors.lastname: Martin-Carbonero
authors.forename: Pablo
authors.initials: P
authors.lastname: Barreiro
authors.forename: Pablo
authors.initials: P
authors.lastname: Rivas
authors.forename: Juan
authors.initials: J
authors.lastname: González-Lahoz
authors.forename: Marina
authors.initials: M
authors.lastname: Núñez
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy*; D006786:Hospitals, Urban; D006801:Humans; D008103:Liver Cirrhosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D013030:Spain / Q000453:epidemiology; D014463:Ultrasonography
chemical_list: D044966:Anti-Retroviral Agents; D000998:Antiviral Agents